Pfizer is pursuing a potentially lucrative area of the vast oncology market. The drugmaker is also targeting the fast-growing weight loss space.
Bank Julius Baer and Co. Ltd Zurich reduced its position in shares of Pfizer Inc. (NYSE: PFE) by 5.3% in the undefined quarter, according to its most recent filing with the Securities and Exchange Com

Pfizer Crosses Below Key Moving Average Level

04:05pm, Thursday, 20'th Nov 2025
In trading on Thursday, shares of Pfizer crossed below their 200 day moving average of $24.58, changing hands as low as $24.28 per share. Pfizer shares are currently trading off about 1.6% on the day.

Is Pfizer's 6.9%-Yielding Dividend Still Safe?

09:30am, Thursday, 20'th Nov 2025
A high-yielding payout hasn't been enough reason for investors to buy Pfizer's stock. The pharmaceutical giant's valuation has been cut in half in just three years.
This article highlights the October 2025 ReFa/Ro Dogs, focusing on high-yield, low-priced dividend stocks for contrarian income investors. Top projected net gainers include MFA, CIM, HAFN, IPG, and LY

Pfizer: Is This Pharma Giant Finally A Bargain

03:51pm, Wednesday, 19'th Nov 2025
Following Pfizer's victory over Novo Nordisk in the "war" for Metsera, its stock resumed its upward momentum. But before the deal was completed, it again beat Wall Street analysts' consensus EPS and r
Pfizer and supplier Tris Pharma reached a $41.5 million settlement with Texas to resolve claims over alleged quality control lapses in medicine to treat attention deficit hyperactivity disorder in chi
Pfizer Inc. ( PFE ) Jefferies London Healthcare Conference 2025 November 19, 2025 4:00 AM EST Company Participants David Denton - Executive VP & CFO Conference Call Participants Akash Tewari - Jefferi
America First Investment Advisors LLC lifted its position in Pfizer Inc. (NYSE: PFE) by 1.6% in the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 796,840 sh
PFE trades above its 50-day SMA on recent gains from the Metsera acquisition and a drug pricing agreement with the U.S. administration.

2 No-Brainer Healthcare Stocks to Buy Now

06:45am, Tuesday, 18'th Nov 2025
Pfizer's acquisition of obesity drugmaker Metsera positions the pharmaceutical giant to compete in a market expected to reach $130 billion by 2030. Viking Therapeutics has both injectable and oral ver
Avantax Advisory Services Inc. raised its stake in Pfizer Inc. (NYSE: PFE) by 14.6% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). Th
Bridger Management LLC cut its stake in Pfizer Inc. (NYSE: PFE) by 12.3% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned
Pfizer's CEO thinks his company will make big waves in the weight loss market. Eli Lilly does have a strong hold on the industry and won't let go anytime soon.
The U.S.-Saudi Arabia investment forum to take place in Washington during the visit of Saudi Crown Prince Mohammed bin Salman this week is expected to include CEOs from Chevron, Qualcomm, Cisco, Gener
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE